• Best CPA Networks
  • Best Cost-Per-Sale Affiliate Networks
  • Best Pay-Per-Call Networks
  • mThink Digital
  • Thought Leadership
    • White Papers
  • About
    • Content Marketing
    • Content Strategy
      • Web Content
      • Social Media Strategy
      • Webinars & Video
      • Thought Leadership
    • Performance Marketing
    • Portfolio
      • Revenue Performance
      • Accenture
      • Microsoft
      • Java Detour
      • Our Process
    • Contact Us

mThink

Blue Book Logo

BlueBook Logo

The Trusted Name in Performance Marketing

Revenue & eCommerce Blog

  • Home
  • Blue Book
    • About Blue Book
    • Blue Ribbon Panel
    • Interviews
    • Research Methodology
    • Back Issues
    • Advertising
      • Website Creative Specifications
      • Newsletter Creative Specifications
  • Best CPA Networks
  • Best Cost-Per-Sale Affiliate Networks
  • Best Pay-Per-Call Networks
  • Best European CPA Networks
  • Best CPA Networks for Affiliates
  • Best CPA Networks for Advertisers

FDA Issues CBD Substantiation Warnings

December 5, 2017 by Richard B. Newman

On November 1, 2017, the Food and Drug Administration (FDA) issued warning letters to four companies with respect to CBD-related claims made in online stores and on social media websites.  The advertising at issue includes phrases like “CBD makes cancer cells commit ‘suicide’ without killing other cells” and “combats tumor and cancer cells.”

In a press announcement, the FDA asserts that the companies are “illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these outcomes.”

Selling products that make such claims without substantiation is a violation of the FTC Act and the Federal Food, Drug and Cosmetic Act.

The FDA has also expressed concern that reliance on the products may cause cancer patients to forego  established treatment options.

“We don’t let companies market products that deliberately prey on sick people with baseless claims that their substance can shrink or cure cancer, and we’re not going to look the other way on enforcing these principles when it comes to marijuana-containing products,” said FDA Commissioner Scott Gottlieb, M.D.

Contact an FTC defense attorney if you are interested in the implementation of preventative compliance measures or are the subject of a regulatory investigation.

Richard B. Newman is an Internet marketing compliance and regulatory defense attorney at Hinch Newman LLP focusing on advertising and digital media matters. His practice includes conducting legal compliance reviews of advertising campaigns, representing clients in investigations and enforcement actions brought by the Federal Trade Commission and state Attorneys General, commercial litigation, advising clients on promotional marketing programs, and negotiating and drafting legal agreements. You can find him on Twitter @FTCLawDefense.  

ADVERTISING MATERIAL. These materials are provided for informational purposes only and are not to be considered legal advice, nor do they create a lawyer-client relationship. No person should act or rely on any information in this article without seeking the advice of an attorney. Information on previous case results does not guarantee a similar future result. Hinch Newman LLP | 40 Wall St., 35thFloor, New York, NY 10005 | (212) 756-8777.

Related posts:

  1. RIP Net Neutrality Net neutrality, the “First Amendment of the Internet,” is the...
  2. FTC Defense Lawyer Alert: Nationwide Crackdown on Student Loan Debt Relief Document Preparation Services Continues Earlier this month, the Federal Trade Commission, along with 11...
  3. FTC Defense Lawyer Alert:  FTC Data Security Enforcement Authority Takes a Hit A District Court in Northern California has recently dismissed multiple...
  4. FTC Defense Lawyer Alert:  FTC Completely Hip to Partials Subscription-based billing models that fail to lawfully disclose material terms...

Filed Under: Blue Book, Revenue Tagged With: CBD, Ftc compliance lawyer, FTC defense attorney, FTC defense lawyer

Search

ROS Column 2 High – 300×250 (Global)

ROS Column 2 Mid – 300×250 (Global)

ROS Column 2 Low – 300×misc (Global)

Subscribe to our newsletter!

* indicates required

Lowest Ad in Column 2 – 300×250

Recent Posts

  • Advertiser’s Responsibilities for What Others Say in Social Media
  • How Publishers Can Leverage Push Notifications To Scale User Engagement
  • FTC Obtains Court Order Banning Alleged Work-From-Home Scammer from Selling Business Opportunities and Using Robocalls
  • Court Holds Professional TCPA Litigant Can Face Fraud-Based Counterclaim
  • Defendant Behind Alleged Bogus Health Insurance Scheme Agrees to Settle FTC Charges
  • How to Set Up a Warm Transfer Campaign Without Breaking the Bank (Step by Step)
  • Five Advertisers Speak Their Minds on the Importance of Network Partnerships, Transparency, and Fraud Prevention
  • Why All Media Buyers Need to Add Pay Per Call in 2021
  • Court Holds No TCPA Standing With Ringless Voice Mail Message
  • Promote E-gift Cards to Drive More Last-Minute Holiday Sales
  • Ecommerce Is On Top Of The World As Consumers Embrace Online Shopping Like Never Before
  • DoJ Announces Historic Civil Penalty in a Telemarketing Enforcement Action
  • How ClickDealer Grew To Be The Best CPA Network In Europe – An Interview with Taras Kiseliuk
  • Why Fewer, Better Customers Is The Way To Thrive – An Interview With Olivier Bourque, CrakRevenue
  • The Best CPA Networks In Europe

About mThink

mThink is a specialist digital marketing company based in San Francisco. We focus on media buying, Facebook marketing, direct response, social and mobile. In addition mThink produces the annual Blue Book Rankings of major performance marketing networks. Read More »

Copyright ©2021 · mThink. All rights reserved.
3053 Fillmore Street, Suite 325 | (415) 787-0250
Disclaimer | Privacy Policy